Risk management of biosimilars in oncology: each medicine is a work in progress

@inproceedings{Vulto2011RiskMO,
  title={Risk management of biosimilars in oncology: each medicine is a work in progress},
  author={Arnold G. Vulto and Stacy A. Crow},
  booktitle={Targeted Oncology},
  year={2011}
}
Drug licensing and drug safety monitoring for standard chemical entities have been established and are routinely used. These have resulted in a solid foundation of knowledge from which confident therapeutic decisions can be made. For many chemical entities, this advanced level of experience is also present for the generic products. The expertise surrounding the development of biosimilar competitor versions is increasing and progress is encouraging. To address the re-engineering and… CONTINUE READING
3
Twitter Mentions

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

a retrospective analysis of direct healthcare professional communications from 1999 to 2009

PG Mol, SM Straus, +3 authors Netherlands Haaijer-Ruskamp FM A decade of safety-related regu the
  • Drug Saf 33(6):463–474. doi:10.2165/11532840-000000000-00000 S48 Targ Oncol
  • 2012
VIEW 1 EXCERPT

Biosimilars: pharmacovigilance and risk management.

  • Pharmacoepidemiology and drug safety
  • 2010
VIEW 1 EXCERPT

Concerns about erythropoiesis stimulating agents in oncology: an update

M Dicato, L Lawny
  • Eur J Hosp Pharm Pract
  • 2009
VIEW 1 EXCERPT

Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2009
VIEW 1 EXCERPT

Erythropoietin in cancer patients.

  • Annual review of medicine
  • 2009
VIEW 1 EXCERPT